No significant clinical benefit with Umifenovir addition in COVID-19 treatment: Glenmark clinical study

▴ No significant clinical benefit with Umifenovir addition in COVID-19 treatment: Glenmark clinical study
Umifenovir did not show superior clinical outcomes when added to Favipiravir treatment. The trial did not meet key end-points

Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, today announced results of its “FAITH” combination trial with antivirals Umifenovir and Favipiravir for the treatment of moderate hospitalized COVID-19 patients. This was the second clinical study after the successful Favipiravir monotherapy trial earlier this year that led the company to receiving the Emergency Use Authorisation for Favipiravir.

This second study titled the FAITH trial evaluated the possible superiority of the combination’s efficacy against Favipiravir monotherapy. As per the results that Glenmark today presented to the regulator, the study showed no superior clinical outcomes with the addition of Umifenovir.

The FAITH study enrolled a total of 158 hospitalized patients with moderate COVID-19 in India. The study’s primary end point (clinical outcome measured) was time taken from randomization to clinical cure, defined as resolution of baseline clinical signs and symptoms of COVID-19 infection and at least 2 point improvement on WHO Ordinal Scale for Clinical Improvement, within a time frame of 28 days. Median time to clinical cure improved by only 1 day (7 as compared to 8) in patients who received the two antiviral combination, which was not statistically significant and did not justify adding two antiviral agents.

Tags : #LatestPharmaNewsOct21 #LatestGlenmarkNewsOct21 #TreatmentofCOVID19 #ResultsofFAITH

About the Author


Sana Farid Khan

“The best way to become acquainted with a subject is to write about it."
A confident counselor, a speaker, and an educator, ready to utilize my communication skills effectively in the world of healthcare by putting pen to paper to reach new heights of success.
You can write to me at [email protected]

Related Stories

Loading Please wait...